Providing molecular diagnosis and monitoring of patients with chronic myeloid leukemia in Abuja, Nigeria
Author(s)
Type
Journal Article
Abstract
The process of managing chronic myeloid leukemia (CML) at the National Hospital Abuja was frustrating to both the clinicians and patients because the hospital did not have facilities for molecular diagnosis, which is a prerequisite to access imatinib mesylate through the Glivec International Patient Assistance Program (GIPAP; free access to imatinib) program. The testing was outsourced, and in addition to being very expensive, the results usually take months to get back to the hospital. In 2014, the International Chronic Myeloid Leukemia Foundation offered clinical CML preceptorship training to C.U. at the Hammersmith Hospital, London, United Kingdom, (Figure 1) under the mentorship of Jane Apperley. In 2016, the International Chronic Myeloid Leukemia Foundation extended the collaboration by providing a grant of $10 000 US dollars for the purchase of a GeneXpert polymerase chain reaction (PCR) machine for the diagnosis and monitoring of CML patients at the National Hospital Abuja. The Max Foundation provided a supplementary grant and donated 50 test kits to set up on-site PCR (GeneXpert) testing for molecular diagnosis and monitoring of CML patients (Figure 2).
Date Issued
2017-12-08
Date Acceptance
2017-12-01
Citation
Blood Advances, 2017, 1 (Supplement 1), pp.29-31
ISSN
2473-9529
Publisher
American Society of Hematology
Start Page
29
End Page
31
Journal / Book Title
Blood Advances
Volume
1
Issue
Supplement 1
Copyright Statement
© 2017 by The American Society of Hematology.
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000417682100010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Subjects
Science & Technology
Life Sciences & Biomedicine
Hematology
Publication Status
Published